Trastuzumab glyco-optimised - Glycotope

Drug Profile

Trastuzumab glyco-optimised - Glycotope

Alternative Names: Glycooptimised TrastuzuMab-GEX; GT-Mab 7.3-GEX; TrasGEX; TrastuzuMab-GEX

Latest Information Update: 24 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Glycotope
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Gastric cancer
  • Phase I Breast cancer

Most Recent Events

  • 24 Jul 2017 Trastuzumab glyco-optimised - Glycotope is available for licensing as of 24 Jul 2017. http://www.glycotope.com/biopharmaceuticals-pipeline/ (Glycotope pipeline, July 2017)
  • 29 Aug 2016 Phase-II clinical trials in Gastric cancer in Germany (IV) (Glycotope pipeline as of August 2016)
  • 23 Mar 2016 Phase I development is ongoing in Austria
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top